M&A Deal Summary |
|
|---|---|
| Date | 2023-07-18 |
| Target | Santen - Branded Ophthalmic Portfolio |
| Sector | Life Science |
| Buyer(s) | Harrow |
| Sellers(s) | Santen Pharmaceutical |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1998 |
| Sector | Life Science |
| Employees | 382 |
| Revenue | 200M USD (2024) |
Harrow is a developer, producer, and dispenser of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Harrow was founded in 1998 and is based in Nashville, Tennessee.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 9 |
| Sector: Life Science M&A | 6 of 7 |
| Type: Divestiture M&A Deals | 6 of 6 |
| Country: Japan M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-27 |
Sintetica - Patented Ophthalmic Surgical Drug Candidate
United States Sintetica's Patented Ophthalmic Surgical Drug Candidate provides ocular surface anesthesia during ophthalmic interventions such as cataract surgery and intravitreal injections. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-09-26 |
Melt
Brentwood, Tennessee, United States Melt is a clinical-stage pharmaceutical company focused on developing proprietary non-IV, non-opioid, sedation, and analgesia therapeutics for human medical procedures in the hospital, outpatient, and in-office settings. The company intends to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway for its proprietary, patented small-molecule product candidates, where possible. Its core intellectual property is the subject of multiple granted patents in North America, Europe, Asia, and the Middle East. Melt is based in Brentwood, Tennessee. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1890 |
| Sector | Life Science |
| Employees | 3,849 |
| Revenue | 300.0B JPY (2025) |
Santen Pharmaceutical is an entity which engages in the research, development, manufacture, and marketing of ophthalmic and anti-rheumatic pharmaceuticals for the protection and enhancement of eyesight and health. Santen Pharmaceutical was founded in 1890 and is based in Osaka, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Japan M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-16 |
Eyevance Pharmaceuticals
Fort Worth, Texas, United States Eyevance Pharmaceuticals is committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision, better quality of life, and address significant unmet medical needs. Eyevance Pharmaceuticals was founded in 2017 and is based in Fort Worth, Texas. |
Buy | - |
